Cure Network Ventures was created in 2015 as a wholly owned, for-profit subsidiary of Gladstone Institutes. It facilitates relationships and synergizes Gladstone science with investors, contract research organizations, and established biopharmaceutical companies.
In 2016, Cure Network Ventures partnered with Dolby Acceleration Partners to create Cure Network Dolby Acceleration Partners in order to develop novel therapeutics for Alzheimer’s disease.